Assays | Oligoarticular JIA, n = 31 | Polyarticular JIA, n = 22 | SpA, n = 16 | IBD-related Arthritis, n = 11 | Healthy Controls, n = 34 |
---|---|---|---|---|---|
Anticore LPS, EIA units, n = 112*, IQR | 333 | 471 | 415 | 318 | 239 |
227–472 | 263–676 | 303–771 | 216–398 | 143–325 | |
p value vs controls | 0.024 | < 0.001 | 0.001 | 0.111 | NA |
LBP, ng/ml, n = 112* IQR | 9.4 | 18.7 | 13.5 | 11.8 | 5.3 |
4.3–22.9 | 9.4–34.7 | 6.7–14.7 | 3.6–17.9 | 1.8–9.0 | |
p value vs controls | 0.002 | 0.001 | 0.006 | 0.108 | NA |
α-1AGP, μg/ml, n = 114 IQR | 1203 | 1398 | 1116 | 759 | 658 |
820–1468 | 1025–1843 | 760–13,867 | 630–991 | 523–908 | |
p value vs controls | 0.001 | 0.001 | 0.003 | 0.185 | NA |
CRP, μg/ml, n = 107* IQR | 2.4 | 12.3 | 2.1 | 0.9 | 0.07 |
0.6–4.2 | 1.1–64.2 | 0.3–4.5 | 0–4.1 | 0–0.7 | |
p value vs controls | 0.001 | < 0.001 | 0.001 | 0.122 | NA |
↵* For some subjects, we had insufficient serum or plasma to perform all EIA, so n for some assays does not always equal 114. LPS: lipopolysaccharide; LBP: LPS-binding protein; α-1AGP: α-1-acid glycoprotein; CRP: C-reactive protein; JIA: juvenile idiopathic arthritis; SpA: spondyloarthropathies; EIA: enzyme immunoassay; IBD: inflammatory bowel disease; NA: not applicable.